Clinical Thyroidology For Patients

Clinical Thyroidology for Patients

Clinical Thyroidology for Patients is a collection of summaries of recently published articles from the medical literature that covers the broad spectrum of thyroid disorders.

These notes describing published research studies were prepared by Ernest Mazzaferri, MD  from summaries of original research articles. The summaries
were published in Clinical Thyroidology, a publication of the
American Thyroid Association. Dr. Mazzaferri is the Editor-in-Chief of Clinical

December 2008 Volume 1 Issue 2

Now available in pdf format for saving and printing and Web page format for viewing online

PDF Format for Saving and Printing
Clinical Thyroidology for Patients December 2008 Volume 1 Issue 2 (PDF file, 323 KB)


  1. THYROID CANCER Motesanib diphosphate can induce partial remissions in patients with progressive advanced metastatic DTC unresponsive to surgery, external beam radiotherapy and 131I.
    Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42.(PDF File for Saving and Printing)
  2. THYROID CANCER Radiation doses delivered to extrathyroidal tissues by 131I is significantly lower in euthyroid patients treated with recombinant human thyrotropin than in hypothyroid patients undergoing thyroid hormone withdrawal.
    Remy H, Borget I, Leboulleux S, Guilabert N, Lavielle F, Garsi J, Bournaud C, Gupta S, Schlumberger M, Ricard M. 131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients. J Nucl Med 2008;49:1445-50.(PDF File for Saving and Printing)
  3. THYROID CANCER Extrathyroidal tissue radiation damage from 131I remnant ablation is significantly less with recombinant human thyrotropin preparation than with thyroid hormone withdrawal.
    Rosario PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 2008;49:1776-82.(PDF File for Saving and Printing)
  4. THYROID NODULES There is debate about the management of patients who have a thyroid nodule that yields indeterminate follicular cytology on fine-needle aspiration biopsy (FNAB). One of the options is to perform a frozen section diagnosis (FSD) at the time of thyroid lobectomy.
    Peng Y, Wang HH. A meta-analysis of comparing fine-needle aspiration and frozen section for evaluating thyroid nodules. Diagn Cytopathol.2008;36:916-920. (PDF File for Saving and Printing)
  5. THYROIDITIS Subacute thyroiditis (SAT) is a self-limited inflammatory disorder of the thyroid. This is a study aimed at further documenting the clinical characteristics of the disorder based on laboratory and imaging studies before treatment.
    Kudo T, Ito M, Kubota S, Fukata S, Miyauchi A. Clinical characteristics of 852 patients with subacute thyroiditis before treatment. Intern Med 2008;47:725-9.(PDF File for Saving and Printing)
  6. SUBCLINICAL HYPOTHYROIDISM Subclinical hyperthyroidism is the most prevalent thyroid dysfunction in older Italians living in Italy and is associated with cognitive impairment. This is a population-based study of persons living in Chianti (Tuscany, Italy).
    Ceresini G, Lauretani F, Maggio M, Ceda GP, Morganti S, Usberti E, Chezzi C, Valcavi R, Bandinelli S, Guralnik JM, Cappola AR, Valenti G, Ferrucci L. Thyroid Function Abnormalities and Cognitive Impairment in Elderly People: Results. (PDF File for Saving and Printing)
  7. THYROID CANCER Papillary thyroid cancer (PTC) recurs in up to 30% of patients. Surgery and radioactive iodine therapy are the mainstays of therapy in such cases. The current ATA treatment guidelines recommend compartment-directed neck surgery for patients with lymph node.
    Schuff, K. G., Weber, S. M., Givi, B., Samuels, M. H., Andersen, P. E., and Cohen, J. I.Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer.Laryngoscope 118(5), 768-775. 2008 (PDF File for Saving and Printing)
  8. GRAVES’ DISEASE IN CHILDREN Relapse of hyperthyroidism in children with Graves’ disease treated with antithyroid drugs.
    Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008;93:3817. (PDF File for Saving and Printing)
  9. GRAVES’ DISEASE IN PREGNANCY Pregnant women with Graves’ disease in remission after antithyroid drug therapy are at high risk of developing recurrent hyperthyroidism during the postpartum period.
    Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, Castellano M, Rosei EA, Chiovato L. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocr. (PDF File for Saving and Printing)